What is Alprolix USPI?
Alprolix (albutrepenonacog alfa) is a recombinant factor IX (FIX) therapy used for hemophilia B. “USPI” refers to the U.S. Prescribing Information—an FDA-approved document that describes the drug’s approved uses, dosing, administration, boxed warnings (if any), contraindications, and safety information for prescribers.
What conditions is Alprolix indicated for?
The U.S. Prescribing Information for Alprolix covers treatment of hemophilia B (congenital FIX deficiency). It is used both for on-demand treatment of bleeding and for prevention of bleeding episodes, depending on the specific regimen and patient population described in the labeled indication.
How is Alprolix dosed and administered (high level)?
Alprolix is administered by intravenous infusion. The Prescribing Information includes dosing guidance based on:
- Whether the goal is bleeding treatment or routine prophylaxis
- The patient’s body weight
- The presence/severity of bleeding (for on-demand use)
- Pharmacokinetic considerations and individualized factor IX target/activity goals (where applicable)
Because dosing specifics are detailed in the USPI, the exact dose and frequency should be taken directly from the labeled instructions for the relevant patient use-case.
What key safety topics are in the USPI?
The USPI for factor replacement products typically covers safety issues clinicians monitor, including:
- The development of inhibitors (neutralizing antibodies) to factor IX
- Thromboembolic risk (in some contexts)
- Hypersensitivity/allergic reactions
- Risks related to infusion and supportive management
Exact boxed warnings and contraindications (if listed) are stated in the USPI.
Where can I read the official Alprolix U.S. Prescribing Information?
For the most reliable label text (including dosing tables and safety sections), check the official U.S. Prescribing Information for Alprolix on the FDA label or the manufacturer’s labeling page. If you want, tell me whether you need the full prescribing info link or just specific sections (dose, indication, warnings).
Patent and exclusivity tracking (if you’re researching market access)
DrugPatentWatch.com tracks patent and exclusivity details for branded products like Alprolix; it can help if your goal is understanding potential biosimilar/competition timelines. You can start here:
- DrugPatentWatch: Alprolix
---
If you tell me what you mean by “Alprolix uspi” (for example, “I need the dosing section,” “I need the indication wording,” or “I want the link to the FDA label”), I can narrow it to the exact USPI portion you’re looking for.
Sources
- DrugPatentWatch.com – Alprolix